PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Acknowledges Generex's Path-breaking Innovations in Oral Insulin Spray Technology - The company's Generex Oral-lyn™, a breakthrough oral insulin spray technology for the treatment of Type-1 and Type-2 diabetes, offers an ideal and noninvasive route for insulin delivery
Frost & Sullivan Acknowledges Generex's Path-breaking Innovations in Oral Insulin Spray Technology

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2007/02/07 - The company's Generex Oral-lyn™, a breakthrough oral insulin spray technology for the treatment of Type-1 and Type-2 diabetes, offers an ideal and noninvasive route for insulin delivery.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frost & Sullivan selected Generex Biotechnology Corporation (Nasdaq: GNBT-News) as the recipient of the 2006 Frost & Sullivan Award for Technology Innovation in the field of diabetic therapies.

Generex's solution plugs the deficiencies of other alternative delivery modes such as insulin patches, insulin pumps, and inhaled insulin, which are not commonly available or cost effective, and may have treatment limitations.

The company uses the buccal drug delivery technology, which it has been pioneering for years, to develop a liquid formulation of human insulin that can be sprayed into the mouth using its proprietary Rapid Mist™ device.

"The main advantage of this technology is that it ensures absorption is limited to the mouth with no entry to the lungs, thus eliminating the risk of pulmonary inflammations," says Frost & Sullivan Research Analyst Sangeetha Prabakar. "Also, unique features such as rapid insulin absorption and shorter activity make Generex Oral-lyn™ an ideal prandial insulin, which can be conveniently administered immediately after meals and causes minimal occurrence of hypoglycemia."

Generex Oral-lyn™ is a dual-use product. For prediabetic people, it serves as a preventive pharmacological agent to delay the onset of diabetes and for patients with type II diabetes; it helps to postpone diabetic complications. It also significantly reduces the enormous costs associated with diabetes therapies and costs resulting from diabetes complications.

"Since the sprayed insulin is absorbed through the buccal mucosa, Generex Oral-lyn™ can prove an effective alternative to painful mealtime insulin injections, thus improving patient compliance -- especially among children," notes Prabakar. "Generex is highly focused toward the commercialization of a novel and painless oral insulin therapy, which is sure to revolutionize the insulin market and the treatment of diabetes."

Presently, Generex Oral-lyn™ is already on the market in South America. The Company is also preparing for a pivotal Phase III study in the USA and worldwide.

Each year Frost & Sullivan presents this Award to the company that has carried out new research, which has resulted in innovations that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The Award recognizes the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Generex Biotechnology Corporation

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Acknowledges Generex's Path-breaking Innovations in Oral Insulin Spray Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Best Practices Awards 
awards[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

ZOLL to Showcase Expanded Portfolio of AEDs at Caravan Salon 2017
MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test
Datalogic Announces New Healthcare Memor X3 HC Mobile Computer
Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System
SelectMDx to be Distributed Across Middle East by IPS Genomix
GE Healthcare Partners with Oritain to Introduce Independent Test to Confirm Country of Origin of Fetal Bovine Serum
Saebo, Inc. Awarded Patent for Low-Profile Stroke Recovery Glove
GE Healthcare and HeartFlow Announce Global Cardiovascular Collaboration
Insulin Delivery Devices Market Size to Expand at 7% CAGR through 2020 Says PMR
Intubation Market Significant Profits Estimated to be Generated by 2025 Says Persistence Market Research
PMR Releases Report for Next Generation IV Infusion Pumps Market Impact of Existing and Emerging Market 2017-2025
Medical Tapes Market to Reach US$ 2Bn by 2024 Reports PMR
Global Pyrogen Testing Market Value Expected to Increase to US$ 1.37 Billion by 2024 Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)